Academic Journal
Targeting HER receptors in cancer
| العنوان: | Targeting HER receptors in cancer |
|---|---|
| المؤلفون: | Ocaña, Alberto, Pandiella, Atanasio |
| بيانات النشر: | Bentham Science Publishers |
| سنة النشر: | 2013 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Diabetes, Cancer, Deregulation, Targeted therapies, EGF ligands, Tumors, Anti-receptor antibodies, Resistances, HER receptors, Kinase inhibitors |
| الوصف: | Receptor tyrosine kinases play important roles in animal development and their deregulation has been linked to several pathologies, including cancer or diabetes. In cancer, the ERBB/HER family of receptors has been shown to participate in the pathophysiology of breast, gastric, colorectal, lung and head and neck tumors. Activation of HER receptors occurs by receptor-receptor interactions facilitated by ligand binding, overexpression or molecular alterations of the HER receptors. The best example is the known role of HER2 in the tumorigenesis of a proportion of breast tumors. In this review, we will describe the biological bases that govern HER receptor activation, and this will represent the bases for the explanation of how to target HER receptors in cancer. We will discuss the current therapeutic options to target HER receptors, which are based on anti-receptor antibodies or small molecule kinase inhibitors. We will also describe current clinical applications and future developments of agents which target HER receptors. Finally, we will mention mechanism of resistance to anti-HER therapies, and will describe options to overcome such resistances. ; Peer Reviewed |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 1381-6128 |
| Relation: | Sí; e-issn: 1873-4286; Current Pharmaceutical Design 19(5): 808-817 (2013); http://hdl.handle.net/10261/134573 |
| الاتاحة: | http://hdl.handle.net/10261/134573 |
| Rights: | none |
| رقم الانضمام: | edsbas.65876A |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.65876A 775 3 Academic Journal academicJournal 775.314270019531 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.65876A&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => http://hdl.handle.net/10261/134573# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Targeting HER receptors in cancer
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Ocaña%2C+Alberto%22">Ocaña, Alberto</searchLink><br /><searchLink fieldCode="AR" term="%22Pandiella%2C+Atanasio%22">Pandiella, Atanasio</searchLink> ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Bentham Science Publishers ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2013 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Diabetes%22">Diabetes</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer%22">Cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Deregulation%22">Deregulation</searchLink><br /><searchLink fieldCode="DE" term="%22Targeted+therapies%22">Targeted therapies</searchLink><br /><searchLink fieldCode="DE" term="%22EGF+ligands%22">EGF ligands</searchLink><br /><searchLink fieldCode="DE" term="%22Tumors%22">Tumors</searchLink><br /><searchLink fieldCode="DE" term="%22Anti-receptor+antibodies%22">Anti-receptor antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22Resistances%22">Resistances</searchLink><br /><searchLink fieldCode="DE" term="%22HER+receptors%22">HER receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Kinase+inhibitors%22">Kinase inhibitors</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Receptor tyrosine kinases play important roles in animal development and their deregulation has been linked to several pathologies, including cancer or diabetes. In cancer, the ERBB/HER family of receptors has been shown to participate in the pathophysiology of breast, gastric, colorectal, lung and head and neck tumors. Activation of HER receptors occurs by receptor-receptor interactions facilitated by ligand binding, overexpression or molecular alterations of the HER receptors. The best example is the known role of HER2 in the tumorigenesis of a proportion of breast tumors. In this review, we will describe the biological bases that govern HER receptor activation, and this will represent the bases for the explanation of how to target HER receptors in cancer. We will discuss the current therapeutic options to target HER receptors, which are based on anti-receptor antibodies or small molecule kinase inhibitors. We will also describe current clinical applications and future developments of agents which target HER receptors. Finally, we will mention mechanism of resistance to anti-HER therapies, and will describe options to overcome such resistances. ; Peer Reviewed ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => unknown ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1381-6128 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => Sí; e-issn: 1873-4286; Current Pharmaceutical Design 19(5): 808-817 (2013); http://hdl.handle.net/10261/134573 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => http://hdl.handle.net/10261/134573 ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => none ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.65876A ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => unknown
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Diabetes
[Type] => general
)
[1] => Array
(
[SubjectFull] => Cancer
[Type] => general
)
[2] => Array
(
[SubjectFull] => Deregulation
[Type] => general
)
[3] => Array
(
[SubjectFull] => Targeted therapies
[Type] => general
)
[4] => Array
(
[SubjectFull] => EGF ligands
[Type] => general
)
[5] => Array
(
[SubjectFull] => Tumors
[Type] => general
)
[6] => Array
(
[SubjectFull] => Anti-receptor antibodies
[Type] => general
)
[7] => Array
(
[SubjectFull] => Resistances
[Type] => general
)
[8] => Array
(
[SubjectFull] => HER receptors
[Type] => general
)
[9] => Array
(
[SubjectFull] => Kinase inhibitors
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Targeting HER receptors in cancer
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ocaña, Alberto
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pandiella, Atanasio
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2013
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 13816128
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
)
)
)
)
)
)
|
| IllustrationInfo |